LENZ Therapeutics (LENZ) Q4 2025 earnings review
The VIZZ Launch is Live: Strong Prescriptions, Exploding Cash Burn
LENZ has officially transitioned to a commercial entity, booking its first $1.6M in VIZZ product revenue. The initial launch metrics are encouraging: over 6,500 unique prescribers and 20,000 filled scripts in Q4. However, establishing a 'category of one' is wildly expensive. SG&A expenses surged 323% YoY to $39.6M as the company scaled its sales force and prepared for a massive Q1 2026 direct-to-consumer (DTC) campaign. With $292M on the balance sheet, the company has ample runway, but the rapid acceleration in cash burn puts immense pressure on Q1 and Q2 prescription refill rates to prove this $79/month cash-pay model is durable.
🐂 Bull Case
Over 6,500 eye care professionals (ECPs) prescribed VIZZ in its first quarter on the market, with more than 55% writing multiple prescriptions. This signals strong early confidence in the clinical profile.
The Q1 2026 launch of the 'Make it VIZZable' DTC campaign featuring Sarah Jessica Parker is already driving up to 10x increases in website traffic, setting the stage for aggressive consumer-led demand.
🐻 Bear Case
The company spent nearly $40M in SG&A in Q4 to generate $1.6M in sales. While expected during a launch phase, the gap between cash burn and revenue generation is massive.
The strategy floods the market with samples. The long-term viability depends entirely on patients converting to and maintaining a recurring out-of-pocket cost, which remains unproven.
⚖️ Verdict: ⚪
Neutral. The initial volume metrics are exactly what you want to see for a new launch, but the true test of VIZZ's commercial viability—recurring paid refills vs. the skyrocketing SG&A burn—won't be visible until mid-2026.
Key Themes
DTC Campaign Activation
After focusing Q4 entirely on building doctor confidence through extensive sampling (70,000+ samples), LENZ activated its consumer demand lever in January 2026. The omni-channel campaign featuring Sarah Jessica Parker on national television (Good Morning America, Today Show) is a critical catalyst. Management noted immediate results with website traffic surging 10x following media activations.
Expanding the Ground Game
To capture the incoming DTC demand, LENZ is aggressively expanding its sales infrastructure. The company is increasing its field sales force from 88 to 117 territories (a 33% expansion), expected to be fully deployed by Q2 2026. This allows for higher frequency engagement with the target 15,000 ECPs.
Real-World Side Effect Profile
A crucial data point contradicting the flawless launch narrative is the adverse reaction profile. The prescribing information notes instillation site irritation (20%) and dim vision (16%). In previous quarters, management acknowledged that stinging and redness were reported more frequently in the real world than anticipated. If the 'wow factor' of improved vision doesn't outweigh transient discomfort, the targeted 45,000 paid prescriptions will not convert into long-term refills.
Superior Pharmacological Mechanism
VIZZ's differentiation relies on its specific mechanism of action: it is the first and only aceclidine-based eye drop. As a predominantly pupil-selective miotic, it interacts with the iris with minimal ciliary muscle stimulation, extending the depth of focus for up to 10 hours. This specifically addresses the primary failure point of the previous market entrant (VUITY), which management claims 'did not work long enough'.
Exponential OPEX Burn Profile
The financial cost of building a 'category of one' is steep. Operating loss accelerated to $38.5M in Q4. With the sales force expanding by 33% and the company launching national network television advertising in Q2 2026, the $39.6M Q4 SG&A run rate is likely the floor, not the ceiling. The company is in a race to achieve critical mass before its $292M cash pile depletes.
Macro Exposure of a Cash-Pay Aesthetic Product
VIZZ is positioned as a lifestyle upgrade over reading glasses, paid entirely out-of-pocket (~$79/month). While management previously argued that quality-of-life products are resilient, a cash-pay model targeting 128 million presbyopes is inherently vulnerable to consumer discretionary spending pullbacks during broader economic downturns.
Other KPIs
Reversing. Following the FDA approval of VIZZ in July 2025, R&D expenses have effectively fallen to zero (down from $5.9M in 24Q4 and $3.8M in 25Q3). The company has completely transitioned from a clinical-stage biotech to a commercial operation.
Stable/Declining. Dropped from the $324M pro forma balance cited after the October 2025 capital raise, reflecting the heavy Q4 cash burn. However, management maintains this is sufficient to fund operations all the way to post-launch positive operating cash flow.
Guidance
Accelerating. With 20,000 scripts filled in Q4, this implies at least 25,000 incremental prescriptions in Q1 2026. This metric is the most critical indicator of whether the DTC campaign and expanded sales force are yielding immediate ROI.
Accelerating. Growing from 6,500 at the end of Q4. Capturing 10,000 unique prescribers represents penetration into roughly two-thirds of their stated 15,000 target ECP universe in just six months on the market.
Accelerating. Expanding from the initial 88-territory footprint. This will drive higher SG&A costs through the first half of 2026 as these new reps are recruited, trained, and deployed.
Key Questions
Refill Conversion Rates
Of the 20,000 scripts filled in Q4, how many were first-time fills versus early refills? What is the baseline expectation for patient retention past month three when the 'novelty' effect wears off?
SG&A Peak Timeline
With the sales force expanding by 33% and national TV advertising scaling in Q2, where do you expect quarterly SG&A expense to peak, and how quickly does the DTC spend taper off once awareness is established?
E-Pharmacy vs Retail Split
What percentage of current volume is flowing through your dedicated e-pharmacy partner versus traditional retail, and are you seeing better adherence rates in the closed-loop digital channel?